Alnylam Pharmaceuticals, Inc. (ALNY) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
ALNY Insider Trading Activity
ALNY Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $10,363 | 2 | 4 |
Sells | $70,057,977 | 44 | 96 |
Related Transactions
| Reitan Colleen F | director | 2 | $10,363 | 1 | $8,383 | $1,980 |
| Tanguler Tolga | EVP, Chief Commercial Officer | 0 | $0 | 4 | $978,236 | $-978,236 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 0 | $0 | 5 | $1.54M | $-1.54M |
| SHARP PHILLIP A | director | 0 | $0 | 1 | $3.09M | $-3.09M |
| SCHULMAN AMY W | director | 0 | $0 | 2 | $5.26M | $-5.26M |
| Ausiello Dennis A | director | 0 | $0 | 1 | $5.31M | $-5.31M |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 0 | $0 | 9 | $8.32M | $-8.32M |
| PYOTT DAVID E I | director | 0 | $0 | 2 | $9.39M | $-9.39M |
| Greenstreet Yvonne | Chief Executive Officer | 0 | $0 | 8 | $15.32M | $-15.32M |
| Garg Pushkal | CMO & EVP Dev & Med Affairs | 0 | $0 | 11 | $20.84M | $-20.84M |
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Alnylam Pharmaceuticals, Inc.
Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $10,363 and sold $70.06M worth of Alnylam Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $10,363 and sold $42.48M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Reitan Colleen F (director) — $10,363.
The last purchase of 4 shares for transaction amount of $1,211 was made by Reitan Colleen F (director) on 2024‑10‑17.
List of Insider Buy and Sell Transactions, Alnylam Pharmaceuticals, Inc.
| 2025-04-16 | Sale | Reitan Colleen F | director | 36 <0.0001% | $232.86 | $8,383 | +11.49% | |
| 2025-03-24 | Sale | Garg Pushkal | CMO & EVP Dev & Med Affairs | 5,445 0.0043% | $300.00 | $1.63M | -12.02% | |
| 2025-03-24 | Sale | PYOTT DAVID E I | director | 7,440 0.0059% | $299.00 | $2.22M | -12.02% | |
| 2025-03-21 | Sale | Garg Pushkal | CMO & EVP Dev & Med Affairs | 4,321 0.0033% | $285.00 | $1.23M | -9.65% | |
| 2025-03-04 | Sale | Garg Pushkal | CMO & EVP Dev & Med Affairs | 808 0.0006% | $241.05 | $194,766 | +4.19% | |
| 2025-03-04 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 844 0.0006% | $241.15 | $203,532 | +4.19% | |
| 2025-03-03 | Sale | Greenstreet Yvonne | Chief Executive Officer | 3,877 0.003% | $243.79 | $945,165 | +3.43% | |
| 2025-03-03 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 1,264 0.001% | $243.78 | $308,141 | +3.43% | |
| 2025-03-03 | Sale | Tanguler Tolga | EVP, Chief Commercial Officer | 471 0.0004% | $243.78 | $114,820 | +3.43% | |
| 2025-03-03 | Sale | Garg Pushkal | CMO & EVP Dev & Med Affairs | 1,749 0.0014% | $243.79 | $426,384 | +3.43% | |
| 2025-03-03 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 1,911 0.0015% | $243.73 | $465,772 | +3.43% | |
| 2025-02-28 | Sale | Greenstreet Yvonne | Chief Executive Officer | 2,900 0.0022% | $241.69 | $700,894 | +1.58% | |
| 2025-02-28 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 796 0.0006% | $241.70 | $192,390 | +1.58% | |
| 2025-02-28 | Sale | Tanguler Tolga | EVP, Chief Commercial Officer | 513 0.0004% | $241.68 | $123,983 | +1.58% | |
| 2025-02-28 | Sale | Garg Pushkal | CMO & EVP Dev & Med Affairs | 935 0.0007% | $241.69 | $225,977 | +1.58% | |
| 2025-02-28 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 496 0.0004% | $241.69 | $119,878 | +1.58% | |
| 2025-02-18 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 1,440 0.0011% | $251.56 | $362,243 | -0.31% | |
| 2025-02-18 | Sale | Garg Pushkal | CMO & EVP Dev & Med Affairs | 1,548 0.0012% | $251.67 | $389,579 | -0.31% | |
| 2025-02-14 | Sale | Greenstreet Yvonne | Chief Executive Officer | 1,213 0.0009% | $255.17 | $309,527 | -2.67% | |
| 2025-02-14 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 967 0.0007% | $255.17 | $246,750 | -2.67% |
Insider Historical Profitability
| Greenstreet Yvonne | Chief Executive Officer | 98635 0.0756% | $26.32M | 0 | 24 | |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 47751 0.0366% | $12.74M | 0 | 9 | |
| Tanguler Tolga | EVP, Chief Commercial Officer | 28011 0.0215% | $7.48M | 0 | 11 | |
| Garg Pushkal | CMO & EVP Dev & Med Affairs | 20221 0.0155% | $5.4M | 0 | 18 | |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 13501 0.0104% | $3.6M | 0 | 9 | |
| SCHULMAN AMY W | director | 8436 0.0065% | $2.25M | 0 | 2 | |
| PYOTT DAVID E I | director | 136 0.0001% | $36,292.96 | 1 | 2 | +45.98% |
| Ausiello Dennis A | director | 136 0.0001% | $36,292.96 | 0 | 10 | |
| SHARP PHILLIP A | director | 0 0% | $0 | 2 | 15 | +68.46% |
| Reitan Colleen F | director | 0 0% | $0 | 2 | 1 | |
| Sanofi | 10 percent owner | 10554134 8.0944% | $2.82B | 6 | 0 | +18.68% |
| NOVARTIS AG | 10 percent owner | 4051002 3.1069% | $1.08B | 3 | 1 | <0.0001% |
| Westphal Christoph H | director, 10 percent owner | 300170 0.2302% | $80.1M | 1 | 0 | +16.38% |
| CHP II LP | 10 percent owner | 232500 0.1783% | $62.04M | 1 | 0 | +16.38% |
| MARAGANORE JOHN | Chief Executive Officer | 214765 0.1647% | $57.31M | 9 | 42 | +49.04% |
| Abingworth Management LTD | 10 percent owner | 155367 0.1192% | $41.46M | 2 | 6 | +44.17% |
| Berriman John E | director | 155367 0.1192% | $41.46M | 1 | 0 | +16.38% |
| Greene Barry E | President | 70343 0.0539% | $18.77M | 7 | 18 | +53.61% |
| POLARIS VENTURE MANAGEMENT CO III LLC | 10 percent owner | 30384 0.0233% | $8.11M | 0 | 23 | |
| Vaishnaw Akshay | President | 22774 0.0175% | $6.08M | 0 | 36 | |
| BONNEY MICHAEL W | director | 16029 0.0123% | $4.28M | 2 | 2 | <0.0001% |
| CLARKE JOHN K | director | 8891 0.0068% | $2.37M | 1 | 2 | |
| ATLAS VENTURE FUND V LP | 10 percent owner | 6557 0.005% | $1.75M | 2 | 2 | +8.19% |
| KEATING LAURIE | EVP, Chief Legal Officer | 5132 0.0039% | $1.37M | 1 | 17 | +78.8% |
| Franchini Indrani Lall | EVP, CLO & Secretary | 4133 0.0032% | $1.1M | 0 | 4 | |
| Reid Laurence | SVP, Chief Business Officer | 3905 0.003% | $1.04M | 1 | 7 | +41.4% |
| Barrett Peter | director | 2647 0.002% | $706,378.42 | 2 | 9 | +8.19% |
| PAUL STEVEN M | 2526 0.0019% | $674,088.36 | 1 | 3 | +10.44% | |
| Gros David-Alexandre C | SVP, Chief Business Officer | 1000 0.0008% | $266,860.00 | 1 | 0 | <0.0001% |
| STARR KEVIN P | director | 0 0% | $0 | 0 | 6 | |
| SCHIMMEL PAUL | director | 0 0% | $0 | 2 | 15 | +27.77% |
| Fanucci Marsha | director | 0 0% | $0 | 1 | 2 | +41.4% |
| VINCENT JAMES L | director | 0 0% | $0 | 0 | 5 | |
| Allen Patricia L | VP of Finance and Treasurer | 0 0% | $0 | 0 | 2 | |
| Mason Michael | VP, Finance and Treasurer | 0 0% | $0 | 0 | 13 |
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $11.77B | |
$159,914,414 | 243 | 18.52% | $7.49B | |
$211,610,344 | 91 | 38.45% | $6.56B | |
$2,765,836 | 72 | 20.00% | $11.46B | |
$2,449,191,716 | 58 | 16.50% | $60.95B | |
$11,789,714 | 49 | 14.35% | $11.97B | |
Alnylam Pharmaceuticals, Inc. (ALNY) | $323,520,369 | 46 | 31.46% | $34.8B |
$88,307,390 | 38 | -1.70% | $6.34B | |
$13,655,378 | 35 | 17.13% | $13.9B | |
$10,499,766 | 34 | 70.55% | $10.18B | |
$15,836,193 | 25 | 17.98% | $110.94B | |
$415,105,240 | 19 | -14.04% | $6.32B | |
$83,065,496 | 16 | 9.40% | $7.44B | |
$152,272,932 | 16 | -10.78% | $18.85B | |
$627,701,115 | 15 | 145.68% | $18.15B | |
$948,235 | 8 | 15.55% | $8.09B | |
$40,276,273 | 4 | 34.57% | $7.68B | |
$4,849,105 | 4 | 2.71% | $6.42B | |
$999,989 | 1 | 262.16% | $9.86B |
ALNY Institutional Investors: Active Positions
| Increased Positions | 338 | +56.62% | 9M | +6.87% |
| Decreased Positions | 258 | -43.22% | 9M | -6.66% |
| New Positions | 96 | New | 1M | New |
| Sold Out Positions | 70 | Sold Out | 673,856 | Sold Out |
| Total Postitions | 677 | +13.4% | 128M | +0.21% |
ALNY Ownership Change vs Market
Institutional Investor Ownership
| Capital World Investors | $4.31M | 12.77% | 16.6M | +92,101 | +0.56% | 2024-12-31 |
| Fmr Llc | $3.5M | 10.37% | 13.49M | -1M | -8.09% | 2024-12-31 |
| Vanguard Group Inc | $3.3M | 9.8% | 12.73M | +98,303 | +0.78% | 2024-12-31 |
| Blackrock, Inc. | $2.48M | 7.35% | 9.56M | -325,875 | -3.3% | 2025-03-31 |
| Capital Research Global Investors | $1.81M | 5.36% | 6.97M | +2M | +32.89% | 2024-12-31 |
| Regeneron Pharmaceuticals, Inc. | $1.15M | 3.42% | 4.44M | 0 | 0% | 2025-03-31 |
| T. Rowe Price Investment Management, Inc. | $1.14M | 3.37% | 4.38M | +1M | +39.66% | 2024-12-31 |
| Wellington Management Group Llp | $1.09M | 3.23% | 4.2M | -756,724 | -15.28% | 2024-12-31 |
| Baillie Gifford & Co | $1.05M | 3.11% | 4.04M | -846,741 | -17.33% | 2024-12-31 |
| Dodge & Cox | $918,309.00 | 2.72% | 3.54M | -82,273 | -2.27% | 2024-12-31 |